Last reviewed · How we verify
Measles-mumps-rubella-varicella vaccine
Measles-mumps-rubella-varicella vaccine is a Live attenuated vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Prevention of measles, mumps, rubella, and varicella in children and adolescents. Also known as: MMRV: ProQuad.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, rubella, and varicella viruses by introducing attenuated (weakened) forms of all four viruses.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, rubella, and varicella viruses by introducing attenuated (weakened) forms of all four viruses. Used for Prevention of measles, mumps, rubella, and varicella in children and adolescents.
At a glance
| Generic name | Measles-mumps-rubella-varicella vaccine |
|---|---|
| Also known as | MMRV: ProQuad |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The MMRV vaccine is a live attenuated vaccine combining four separate viral vaccines into a single formulation. Each component virus is weakened so it cannot cause disease but retains sufficient immunogenicity to trigger both humoral (antibody) and cell-mediated immune responses. This dual immune activation provides long-term protection against infection with wild-type measles, mumps, rubella, and varicella-zoster viruses.
Approved indications
- Prevention of measles, mumps, rubella, and varicella in children and adolescents
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Parotitis
Key clinical trials
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age (PHASE3)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Measles-mumps-rubella-varicella vaccine CI brief — competitive landscape report
- Measles-mumps-rubella-varicella vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Measles-mumps-rubella-varicella vaccine
What is Measles-mumps-rubella-varicella vaccine?
How does Measles-mumps-rubella-varicella vaccine work?
What is Measles-mumps-rubella-varicella vaccine used for?
Who makes Measles-mumps-rubella-varicella vaccine?
Is Measles-mumps-rubella-varicella vaccine also known as anything else?
What drug class is Measles-mumps-rubella-varicella vaccine in?
What development phase is Measles-mumps-rubella-varicella vaccine in?
What are the side effects of Measles-mumps-rubella-varicella vaccine?
Related
- Drug class: All Live attenuated vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of measles, mumps, rubella, and varicella in children and adolescents
- Also known as: MMRV: ProQuad
- Compare: Measles-mumps-rubella-varicella vaccine vs similar drugs
- Pricing: Measles-mumps-rubella-varicella vaccine cost, discount & access